注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要从事生物科技产品的发现、开发、生产及商业化。该公司的主要产品包括用于治疗复发╱难治性多发性骨髓瘤、复发╱难治性弥漫大B细胞淋巴瘤和非小细胞肺癌的ATG-010(selinexor)及用于治疗肝细胞癌和非小细胞肺癌等多种适应症的ATG-008(onatasertib)。该公司主要在亚太地区开展业务。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Jay Mei | 55 | 2018 | Founder, Chairman & CEO |
Donald Andrew Lung | 40 | 2020 | CFO & Executive Director |
Shaji K. Kumar | - | - | Member of Scientific Advisory Board |
Sheng Tang | 38 | 2020 | Independent Non-Executive Director |
Joseph Camardo | 70 | - | Member of Scientific Advisory Board |
Jing Qian | 46 | 2020 | Independent Non-Executive Director |
Robert Gale | - | - | Member of Scientific Advisory Board |
Kan Chen | 41 | 2021 | Non-Executive Director |
Timothy M. Block | 68 | - | Member of Scientific Advisory Board |
Jeffrey Barrett | - | - | Member of Scientific Advisory Board |
Wei-Li Zhao | - | - | Member of Scientific Advisory Board |
Ricky Johnstone | - | - | Member of Scientific Advisory Board |
Florence Houn | - | - | Member of the Scientific Advisory Board |
Rafael Fonseca | 56 | 2023 | Independent Non-Executive Director |
Jayesh Desai | - | 2023 | Member of Scientific Advisory Board |
Yi-Long Wu | - | 2023 | Member of Scientific Advisory Board |
John F. Chin | 57 | 2020 | Executive Director & Chief Business Officer |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核